Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pain
Biotech
Polyrizon pays $3M for license to SciSparc's CB2R agonist
Israeli biotech SciSparc has sold the license for its CB2R agonist to its partner Polyrizon to further develop as a pain therapy.
James Waldron
Aug 19, 2024 5:27am
The neural circuits behind the placebo effect
Jul 24, 2024 9:02am
AI may influence whether you can get pain medication
Aug 31, 2023 9:25am
Gene therapy reduces chronic pain and chemo-induced neuropathy
Jul 31, 2023 9:30am
Heron lays off 25% of staff in second round of cuts in 13 months
Jul 24, 2023 12:44pm
Eliem axes depression drug, lays off 55% of team to stretch cash
Feb 10, 2023 6:00am